Antimüllerian hormone among women with and without type 1 diabetes: the Epidemiology of Diabetes Interventions and Complications Study and the Michigan Bone Health and Metabolism Study
Catherine Kim, Carrie A Karvonen-Gutierrez, Shengchun Kong et al. · Fertility and Sterility · 2016
Cited by 27 works. doi:10.1016/j.fertnstert.2016.07.009 Open-access PDF
Authors
- Catherine Kim
- Carrie A Karvonen-Gutierrez
- Shengchun Kong
- Valerie L. Arends
- Michael W. Steffes
- Daniel S McConnell
- John F. Randolph
- Sioḃán D. Harlow
References
- The Diagnosis of Polycystic Ovary Syndrome during Adolescence
- Retinopathy and Nephropathy in Patients with Type 1 Diabetes Four Years after a Trial of Intensive Therapy
- Advanced Glycation End Products
- Modern-Day Clinical Course of Type 1 Diabetes Mellitus After 30 Years' Duration
- Effect of Excessive Weight Gain With Intensive Therapy of Type 1 Diabetes on Lipid Levels and Blood Pressure
- The physiology and clinical utility of anti-Müllerian hormone in women
- Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries
- Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications
- Testing and interpreting measures of ovarian reserve: a committee opinion
- Anti-Müllerian Hormone Predicts Menopause: A Long-Term Follow-Up Study in Normoovulatory Women